Pre-clinical models of cognitive dysfunction in schizophrenia: New avenues to addressing unmet needs

Clinical Neuroscience Research

Volumn 3, Issue 4-5, 2003, Pages 303-313

  Jentsch, J David ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Animal models; Cogntive dysfunction; Schizophrenia

Indexed keywords

CLOZAPINE; DOPAMINE; DOPAMINE 1 RECEPTOR; KETAMINE; NEUROLEPTIC AGENT; OLANZAPINE; PHENCYCLIDINE; RISPERIDONE; TETRAHYDROCANNABINOL;

ANIMAL MODEL; ATTENTION; CLINICAL FEATURE; COGNITION; COGNITIVE DEFECT; DATA ANALYSIS; DRUG EFFICACY; FRONTAL CORTEX; MAZE TEST; MEDICAL RESEARCH; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RAT; REVIEW; SCHIZOPHRENIA; SOCIAL PSYCHOLOGY; SYMPTOMATOLOGY; TASK PERFORMANCE; VALIDATION PROCESS; WORKING MEMORY;

EID: 0344442803     PISSN: 15662772     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cnr.2003.10.011     Document Type: Review

References (137)

1. Lipska B.K. Weinberger D.R. To model a psychiatric disorder in animals: schizophrenia as a reality test Neuropsychopharmacology 23 3 2000 223-239
2. Jentsch J.D. Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia Neuropsychopharmacology 20 3 1999 201-225
3. Olney J.W. Newcomer J.W. Farber N.B. NMDA receptor hypofunction model of schizophrenia J Psychiatr Res 33 6 1999 523-533
4. Swerdlow N.R. Braff D.L. Geyer M.A. Animal models of deficient sensorimotor gating: what we know, what we think we know, and what we hope to know soon Behav Pharmacol 11 3-4 2000 185-204
5. Geyer M.A. Krebs-Thomson K. Braff D.L. Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review Psychopharmacology (Berl) 156 2-3 2001 117-154
6. Swerdlow N.R. Geyer M.A. Braff D.L. Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges Psychopharmacology (Berl) 156 2-3 2001 194-215
7. Brekke J.S. Kohrt B. Green M.F. Neuropsychological functioning as a moderator of the relationship between psychosocial functioning and the subjective experience of self and life in schizophrenia Schizophr Bull 27 4 2001 697-708
8. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153 3 1996 321-330
9. Green M.F. Kern R.S. Braff D.L. Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the 'right stuff'? Schizophr Bull 26 1 2000 119-136
10. Green M.F. Nuechterlein K.H. Should schizophrenia be treated as a neurocognitive disorder? Schizophr Bull 25 2 1999 309-319
11. Elvevag B. Goldberg T.E. Cognitive impairment in schizophrenia is the core of the disorder Crit Rev Neurobiol 14 1 2000 1-21
12. Cannon T.D. Gasperoni T.L. van Erp T.G. Rosso I.M. Quantitative neural indicators of liability to schizophrenia: implications for molecular genetic studies Am J Med Genet 105 1 2001 16-19
13. Cornblatt B.A. Malhotra A.K. Impaired attention as an endophenotype for molecular genetic studies of schizophrenia Am J Med Genet 105 1 2001 11-15
14. Baddeley A. The fractionation of working memory Proc Natl Acad Sci USA 93 24 1996 13468-13472
15. Baddeley A. Recent developments in working memory Curr Opin Neurobiol 8 2 1998 234-238
16. Baddeley A. Chincotta D. Adlam A. Working memory and the control of action: evidence from task switching J Exp Psychol Gen 130 4 2001 641-657
17. Baddeley A. Della Sala S. Working memory and executive control Philos Trans R Soc Lond B Biol Sci 351 1346 1996 1397-1403 discussion 1403-4
18. Park S. Holzman P.S. Schizophrenics show spatial working memory deficits Arch Gen Psychiatry 49 12 1992 975-982
19. Callicott J.H. Bertolino A.Mattay V.S. et al. Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited Cereb Cortex 10 11 2000 1078-1092
20. Meyer-Lindenberg A. Poline J.B. Kohn P.D. et al. Evidence for abnormal cortical functional connectivity during working memory in schizophrenia Am J Psychiatry 158 11 2001 1809-1817
21. Goldman-Rakic P.S. The physiological approach: functional architecture of working memory and disordered cognition in schizophrenia Biol Psychiatry 46 5 1999 650-661
22. Olton D.S. The radial arm maze as a tool in behavioural pharmacology Physiol Behav 40 6 1987 793-797
23. Seamans J.K. Floresco S.B. Phillips A.G. D1 receptor modulation of hippocampal-prefrontal cortical circuits integrating spatial memory with executive functions in the rat J Neurosci 18 4 1998 1613-1621
24. Murphy B.L. Arnsten A.F. Jentsch J.D. Roth R.H. Dopamine and spatial working memory in rats and monkeys: pharmacological reversal of stress-induced impairment J Neurosci 16 23 1996 7768-7775
25. Jentsch J.D. Andrusiak E. Tran A. Bowers M.B. Jr Roth R.H. Delta 9-tetrahydrocannabinol increases prefrontal cortical catecholaminergic utilization and impairs spatial working memory in the rat: blockade of dopaminergic effects with HA966 Neuropsychopharmacology 16 6 1997 426-432
26. Lipska B.K. Aultman J.M. Verma A. Weinberger D.R. Moghaddam B. Neonatal damage of the ventral hippocampus impairs working memory in the rat Neuropsychopharmacology 27 1 2002 47-54
27. Floresco S.B. Seamans J.K. Phillips A.G. Differential effects of lidocaine infusions into the ventral CA1/subiculum or the nucleus accumbens on the acquisition and retention of spatial information Behav Brain Res 81 1-2 1996 163-171
28. Kesner R.P. Dakis M. Bolland B.L. Phencyclidine disrupts long-but not short-term memory within a spatial learning task Psychopharmacology (Berl) 111 1 1993 85-90
29. Varvel S.A. Hamm R.J. Martin B.R. Lichtman A.H. Differential effects of delta 9-THC on spatial reference and working memory in mice Psychopharmacology (Berl) 157 2 2001 142-150
30. Baron S.P. Wright D. Wenger G.R. Effects of drugs of abuse and scopolamine on memory in rats: delayed spatial alternation and matching to position Psychopharmacology (Berl) 137 1 1998 7-14
31. Bushnell P.J. Levin E.D. Effects of dopaminergic drugs on working and reference memory in rats Pharmacol Biochem Behav 45 4 1993 765-776
32. Kesner R.P. Bierley R.A. Pebbles P. Short-term memory: the role of d-amphetamine Pharmacol Biochem Behav 15 5 1981 673-676
33. Bauer R.H. Fuster J.M. Effects of d-amphetamine and prefrontal cortical cooling on delayed matching-to-sample behavior Pharmacol Biochem Behav 8 3 1978 243-249
34. Mattay V.S. Callicott J.H. Bertolino A. et al. Effects of dextroamphetamine on cognitive performance and cortical activation Neuroimage 12 3 2000 268-275
35. Jentsch J.D. Tran A. Le D. Youngren K.D. Roth R.H. Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat Neuropsychopharmacology 17 2 1997 92-99
36. Moghaddam B. Adams B.W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats Science 281 5381 1998 1349-1352
37. Nava F. Carta G. Battasi A.M. Gessa G.L. D(2) dopamine receptors enable delta(9)-tetrahydrocannabinol induced memory impairment and reduction of hippocampal extracellular acetylcholine concentration Br J Pharmacol 130 6 2000 1201-1210
38. Verma A. Moghaddam B. NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine J Neurosci 16 1 1996 373-379
39. Jentsch J.D. Redmond D.E.Jr Elsworth J.D. Taylor J.R. Youngren K.D. Roth R.H. Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine Science 277 5328 1997 953-955
40. Ornstein T.J. Iddon J.L. Baldacchino A.M. et al. Profiles of cognitive dysfunction in chronic amphetamine and heroin abusers Neuropsychopharmacology 23 2 2000 113-126
41. Skosnik P.D. Spatz-Glenn L. Park S. Cannabis use is associated with schizotypy and attentional disinhibition Schizophr Res 48 1 2001 83-92
42. Soueif M.I. Differential association between chronic cannabis use and brain function deficits Ann N Y Acad Sci 282 1976 323-343
43. Ferraro D.P. Grilly D.M. Effects of chronic exposure to delta9-tetrahydrocannabinol on delayed matching-to-sample in chimpanzees Psychopharmacologia 37 4 1974 127-138
44. Chambers R.A. Moore J. McEvoy J.P. Levin E.D. Cognitive effects of neonatal hippocampal lesions in a rat model of schizophrenia Neuropsychopharmacology 15 6 1996 587-594
45. Goldman-Rakic P.S. Selemon L.D. Functional and anatomical aspects of prefrontal pathology in schizophrenia Schizophr Bull 23 3 1997 437-458
46. Lewis D.A. GABAergic local circuit neurons and prefrontal cortical dysfunction in schizophrenia Brain Res Brain Res Rev 31 2-3 2000 270-276
47. Lewis D.A. Levitt P. Schizophrenia as a disorder of neurodevelopment Annu Rev Neurosci 25 2002 409-432
48. Berman K.F. Zec R.F. Weinberger D.R. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. II. Role of neuroleptic treatment, attention, and mental effort Arch Gen Psychiatry 43 2 1986 126-135
49. Callicott J.H. Ramsey N.F. Tallent K. et al. Functional magnetic resonance imaging brain mapping in psychiatry: methodological issues illustrated in a study of working memory in schizophrenia Neuropsychopharmacology 18 3 1998 186-196
50. Aultman J.M. Moghaddam B. Distinct contributions of glutamate and dopamine receptors to temporal aspects of rodent working memory using a clinically relevant task Psychopharmacology (Berl) 153 3 2001 353-364
51. Floresco S.B. Braaksma D.N. Phillips A.G. Thalamic-cortical-striatal circuitry subserves working memory during delayed responding on a radial arm maze J Neurosci 19 24 1999 11061-11071
52. Floresco S.B. Seamans J.K. Phillips A.G. Selective roles for hippocampal, prefrontal cortical, and ventral striatal circuits in radial-arm maze tasks with or without a delay J Neurosci 17 5 1997 1880-1890
53. Seamans J.K. Phillips A.G. Selective memory impairments produced by transient lidocaine-induced lesions of the nucleus accumbens in rats Behav Neurosci 108 3 1994 456-468
54. Knable M.B. Weinberger D.R. Dopamine, the prefrontal cortex and schizophrenia J Psychopharmacol 11 2 1997 123-131
55. Weinberger D.R. Egan M.F. Bertolino A. et al. Prefrontal neurons and the genetics of schizophrenia Biol Psychiatry 50 11 2001 825-844
56. Abi-Dargham A. Mawlawi O. Lombardo I. et al. Prefrontal dopamine D1 receptors and working memory in schizophrenia J Neurosci 22 9 2002 3708-3719
57. Brozoski T.J. Brown R.M. Rosvold H.E. Goldman P.S. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey Science 205 4409 1979 929-932
58. Roberts A.C. De Salvia M.A. Wilkinson L.S. et al. 6-Hydroxydopamine lesions of the prefrontal cortex in monkeys enhance performance on an analog of the Wisconsin Card Sort Test: possible interactions with subcortical dopamine J Neurosci 14 5 Pt 1 1994 2531-2544
59. Crofts H.S. Dalley J.W. Collins P. et al. Differential effects of 6-OHDA lesions of the frontal cortex and caudate nucleus on the ability to acquire an attentional set Cereb Cortex 11 11 2001 1015-1026
60. Sawaguchi T. Goldman-Rakic P.S. D1 dopamine receptors in prefrontal cortex: involvement in working memory Science 251 4996 1991 947-950
61. Mizoguchi K. Yuzurihara M. Ishige A. Sasaki H. Chui D.H. Tabira T. Chronic stress induces impairment of spatial working memory because of prefrontal dopaminergic dysfunction J Neurosci 20 4 2000 1568-1574
62. Castner S.A. Williams G.V. Goldman-Rakic P.S. Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation Science 287 5460 2000 2020-2022
63. Glahn D.C. Kim J. Cohen M.S. et al. Maintenance and manipulation in spatial working memory: dissociations in the prefrontal cortex Neuroimage 17 1 2002 201-213
64. Cannon T.D. Huttunen M.O. Lonnqvist J. et al. The inheritance of neuropsychological dysfunction in twins discordant for schizophrenia Am J Hum Genet 67 2 2000 369-382
65. Clare L. McKenna P.J. Mortimer A.M. Baddeley A.D. Memory in schizophrenia: what is impaired and what is preserved? Neuropsychologia 31 11 1993 1225-1241
66. Heckers S. Rauch S.L. Goff D. et al. Impaired recruitment of the hippocampus during conscious recollection in schizophrenia Nat Neurosci 1 4 1998 318-323
67. Heckers S. Curran T. Goff D. et al. Abnormalities in the thalamus and prefrontal cortex during episodic object recognition in schizophrenia Biol Psychiatry 48 7 2000 651-657
68. Heckers S. Goff D. Schacter D.L. et al. Functional imaging of memory retrieval in deficit vs non-deficit schizophrenia Arch Gen Psychiatry 56 12 1999 1117-1123
69. Kuperberg G. Heckers S. Schizophrenia and cognitive function Curr Opin Neurobiol 10 2 2000 205-210
70. Weiss A.P. Schacter D.L. Goff D. et al. Impaired hippocampal recruitment during normal modulation of memory performance in schizophrenia Biol Psychiatry 53 1 2003 48-55
71. Baxter M.G. Murray E.A. Opposite relationship of hippocampal and rhinal cortex damage to delayed non-matching-to-sample deficits in monkeys Hippocampus 11 1 2001 61-71
72. Bachevalier J. Alvarado M.C. Malkova L. Memory and socioemotional behavior in monkeys after hippocampal damage incurred in infancy or in adulthood Biol Psychiatry 46 3 1999 329-339
73. Murray E.A. Richmond B.J. Role of perirhinal cortex in object perception, memory, and associations Curr Opin Neurobiol 11 2 2001 188-193
74. Hlinak Z. Krejci I. Effects of excitatory amino acid antagonists on social recognition of male rats Behav Pharmacol 5 3 1994 239-244
75. Aigner T.G. Delta-9-tetrahydrocannabinol impairs visual recognition memory but not discrimination learning in rhesus monkeys Psychopharmacology (Berl) 95 4 1988 507-511
76. Ciccocioppo R. Antonelli L. Biondini M. Perfumi M. Pompei P. Massi M. Memory impairment following combined exposure to delta(9 )-tetrahydrocannabinol and ethanol in rats Eur J Pharmacol 449 3 2002 245-252
77. Kesner R.P. Dakis M. Phencyclidine disrupts acquisition and retention performance within a spatial continuous recognition memory task Pharmacol Biochem Behav 44 2 1993 419-424
78. Kesner R.P. Dakis M. Intrahippocampal injections of phencyclidine but not naloxone disrupt acquisition of a spatial continuous recognition memory task Pharmacol Biochem Behav 56 1 1997 97-101
79. Kogan J.H. Frankland P.W. Silva A.J. Long-term memory underlying hippocampus-dependent social recognition in mice Hippocampus 10 1 2000 47-56
80. Clark R.E. West A.N. Zola S.M. Squire L.R. Rats with lesions of the hippocampus are impaired on the delayed non-matching-to-sample task Hippocampus 11 2 2001 176-186
81. Clark R.E. Zola S.M. Squire L.R. Impaired recognition memory in rats after damage to the hippocampus J Neurosci 20 23 2000 8853-8860
82. Zola S.M. Squire L.R. Teng E. Stefanacci L. Buffalo E.A. Clark R.E. Impaired recognition memory in monkeys after damage limited to the hippocampal region J Neurosci 20 1 2000 451-463
83. Cornblatt B.A. Risch N.J. Faris G. Friedman D. Erlenmeyer-Kimling L. The Continuous Performance Test, identical pairs version (CPT-IP): I. New findings about sustained attention in normal families Psychiatry Res 26 2 1988 223-238
84. Earle-Boyer E.A. Serper M.R. Davidson M. Harvey P.D. Continuous performance tests in schizophrenic patients: stimulus and medication effects on performance Psychiatry Res 37 1 1991 47-56
85. Elvevag B. Weinberger D.R. Suter J.C. Goldberg T.E. Continuous performance test and schizophrenia: a test of stimulus-response compatibility, working memory, response readiness, or none of the above? Am J Psychiatry 157 5 2000 772-780
86. Finkelstein J.R. Cannon T.D. Gur R.E. Gur R.C. Moberg P. Attentional dysfunctions in neuroleptic-naive and neuroleptic-withdrawn schizophrenic patients and their siblings J Abnorm Psychol 106 2 1997 203-212
87. Green M.F. Nuechterlein K.H. Gaier D.J. Sustained and selective attention in schizophrenia Prog Exp Pers Psychopathol Res 15 1992 290-313
88. Kurtz M.M. Ragland J.D. Bilker W. Gur R.C. Gur R.E. Comparison of the continuous performance test with and without working memory demands in healthy controls and patients with schizophrenia Schizophr Res 48 2-3 2001 307-316
89. Liu S.K. Chen W.J. Chang C.J. Lin H.N. Effects of atypical neuroleptics on sustained attention deficits in schizophrenia: a trial of risperidone versus haloperidol Neuropsychopharmacology 22 3 2000 311-319
90. Maruff P. Pantelis C. Danckert J. Smith D. Currie J. Deficits in the endogenous redirection of covert visual attention in chronic schizophrenia Neuropsychologia 34 11 1996 1079-1084
91. Mass R. Wolf K. Wagner M. Haasen C. Differential sustained attention/vigilance changes over time in schizophrenics and controls during a degraded stimulus Continuous Performance Test Eur Arch Psychiatry Clin Neurosci 250 1 2000 24-30
92. Nestor P.G. Faux S.F. McCarley R.W. Shenton M.E. Sands S.F. Measurement of visual sustained attention in schizophrenia using signal detection analysis and a newly developed computerized CPT task Schizophr Res 3 5-6 1990 329-332
93. Nuechterlein K.H. Reaction time and attention in schizophrenia: a critical evaluation of the data and theories Schizophr Bull 3 3 1977 373-428
94. Green M. Walker E. Attentional performance in positive- and negative-symptom schizophrenia J Nerv Ment Dis 174 4 1986 208-213
95. Jones L.A. Cardno A.G. Sanders R.D. Owen M.J. Williams J. Sustained and selective attention as measures of genetic liability to schizophrenia Schizophr Res 48 2-3 2001 263-272
96. Laurent A. Biloa-Tang M. Bougerol T. et al. Executive/attentional performance and measures of schizotypy in patients with schizophrenia and in their non-psychotic first-degree relatives Schizophr Res 46 2-3 2000 269-283
97. Pantelis C. Barber F.Z. Barnes T.R. Nelson H.E. Owen A.M. Robbins T.W. Comparison of set-shifting ability in patients with chronic schizophrenia and frontal lobe damage Schizophr Res 37 3 1999 251-270
98. Strandburg R.J. Marsh J.T. Brown W.S. et al. Continuous-processing related ERPS in adult schizophrenia: continuity with childhood onset schizophrenia Biol Psychiatry 45 10 1999 1356-1369
99. Buchsbaum M.S. Nuechterlein K.H. Haier R.J. et al. Glucose metabolic rate in normals and schizophrenics during the Continuous Performance Test assessed by positron emission tomography Br J Psychiatry 156 1990 216-227
100. Cornblatt B.A. Lenzenweger M.F. Erlenmeyer-Kimling L. The continuous performance test, identical pairs version: II. Contrasting attentional profiles in schizophrenic and depressed patients Psychiatry Res 29 1 1989 65-85
101. Siegel B.V.Jr Nuechterlein K.H. Abel L. Wu J.C. Buchsbaum M.S. Glucose metabolic correlates of continuous performance test performance in adults with a history of infantile autism, schizophrenics, and controls Schizophr Res 17 1 1995 85-94
102. Wiedl K.H. Wienobst J. Schottke H.H. Green M.F. Nuechterlein K.H. Attentional characteristics of schizophrenia patients differing in learning proficiency on the Wisconsin Card Sorting Test Schizophr Bull 27 4 2001 687-695
103. Servan-Schreiber D. Cohen J.D. Steingard S. Schizophrenic deficits in the processing of context. A test of a theoretical model Arch Gen Psychiatry 53 12 1996 1105-1112
104. Javitt D.C. Shelley A.M. Silipo G. Lieberman J.A. Deficits in auditory and visual context-dependent processing in schizophrenia: defining the pattern Arch Gen Psychiatry 57 12 2000 1131-1137
105. Moser P.C. Hitchcock J.M. Lister S. Moran P.M. The pharmacology of latent inhibition as an animal model of schizophrenia Brain Res Brain Res Rev 33 2-3 2000 275-307
106. Weiner I. Shadach E. Tarrasch R. Kidron R. Feldon J. The latent inhibition model of schizophrenia: further validation using the atypical neuroleptic, clozapine Biol Psychiatry 40 9 1996 834-843
107. Feldon J. Weiner I. From an animal model of an attentional deficit towards new insights into the pathophysiology of schizophrenia J Psychiatr Res 26 4 1992 345-366
108. Williams J.H. Wellman N.A. Geaney D.P. Cowen P.J. Feldon J. Rawlins J.N. Reduced latent inhibition in people with schizophrenia: an effect of psychosis or of its treatment Br J Psychiatry 172 1998 243-249
109. Escobar M. Oberling P. Miller R.R. Associative deficit accounts of disrupted latent inhibition and blocking in schizophrenia Neurosci Biobehav Rev 26 2 2002 203-216
110. Killcross A.S. Dickinson A. Robbins T.W. Amphetamine-induced disruptions of latent inhibition are reinforcer mediated: implications for animal models of schizophrenic attentional dysfunction Psychopharmacology (Berl) 115 1-2 1994 185-195
111. Robbins T.W. The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry Psychopharmacology (Berl) 163 3-4 2002 362-380
112. Carli M. Evenden J.L. Robbins T.W. Depletion of unilateral striatal dopamine impairs initiation of contralateral actions and not sensory attention Nature 313 6004 1985 679-682
113. Jentsch J.D. Genetic vasopressin deficiency facilitates performance of a lateralized reaction time task: altered attention and motor processes J Neurosci 23 3 2003 1066-1071
114. Grottick A.J. Higgins G.A. Effect of subtype selective nicotinic compounds on attention as assessed by the five-choice serial reaction time task Behav Brain Res 117 1-2 2000 197-208
115. Presburger G. Robinson J.K. Spatial signal detection in rats is differentially disrupted by delta-9-tetrahydrocannabinol, scopolamine, and MK-801 Behav Brain Res 99 1 1999 27-34
116. Jin J. Yamamoto T. Watanabe S. The involvement of sigma receptors in the choice reaction performance deficits induced by phencyclidine Eur J Pharmacol 319 2-3 1997 147-152
117. Arguello P.A. Jentsch J.D. Cannabinoidergic regulation of visuospatial attention in the rat Soc Neurosci Abstr 32 2002 49618
118. Brown V.J. Bowman E.M. Rodent models of prefrontal cortical function Trends Neurosci 25 7 2002 340-343
119. Roberts A.C. Comparison of cognitive function in human and non-human primates Brain Res Cogn Brain Res 3 3-4 1996 319-327
120. Addington J. Addington D. Gasbarre L. Neurocognitive and social functioning in schizophrenia and other diagnoses Schizophr Res 48 2-3 2001 367-368
121. Calarge C. Social cognition and schizophrenia Am J Psychiatry 160 2 2003 405
122. Grady C.L. Keightley M.L. Studies of altered social cognition in neuropsychiatric disorders using functional neuroimaging Can J Psychiatry 47 4 2002 327-336
123. Green M.F. Braff D.L. Translating the basic and clinical cognitive neuroscience of schizophrenia to drug development and clinical trials of antipsychotic medications Biol Psychiatry 49 4 2001 374-384
124. Penn D.L. Some reflections on social-cognitive research in schizophrenia Psychiatry 63 4 2000 339-343
125. Pollice R. Roncone R. Falloon I.R. et al. Is theory of mind in schizophrenia more strongly associated with clinical and social functioning than with neurocognitive deficits? Psychopathology 35 5 2002 280-288
126. Corrigan P.W. Buican B. Toomey R. Construct validity of two tests of social cognition in schizophrenia Psychiatry Res 63 1 1996 77-82
127. Corrigan P.W. Green M.F. Schizophrenic patients' sensitivity to social cues: the role of abstraction Am J Psychiatry 150 4 1993 589-594
128. Penn D.L. Corrigan P.W. Bentall R.P. Racenstein J.M. Newman L. Social cognition in schizophrenia Psychol Bull 121 1 1997 114-132
129. Hare B. Brown M. Williamson C. Tomasello M. The domestication of social cognition in dogs Science 298 5598 2002 1634-1636
130. Ferguson J.N. Aldag J.M. Insel T.R. Young L.J. Oxytocin in the medial amygdala is essential for social recognition in the mouse J Neurosci 21 20 2001 8278-8285
131. Amaral D.G. Bauman M.D. Capitanio J.P. et al. The amygdala: is it an essential component of the neural network for social cognition? Neuropsychologia 41 4 2003 517-522
132. Prather M.D. Lavenex P. Mauldin-Jourdain M.L. et al. Increased social fear and decreased fear of objects in monkeys with neonatal amygdala lesions Neuroscience 106 4 2001 653-658
133. Kesner R.P. Hardy J.D. Novak J.M. Phencyclidine and behavior: II. Active avoidance learning and radial arm maze performance Pharmacol Biochem Behav 18 3 1983 351-356
134. Lichtman A.H. Martin B.R. Delta 9-tetrahydrocannabinol impairs spatial memory through a cannabinoid receptor mechanism Psychopharmacology (Berl) 126 2 1996 125-131
135. Moghaddam B. Adams B. Verma A. Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex J Neurosci 17 8 1997 2921-2927
136. Wiley J.L. Willmore C.B. Effects of nitric oxide synthase inhibitors on timing and short-term memory in rats Behav Pharmacol 11 5 2000 421-429
137. Mallet P.E. Beninger R.J. The cannabinoid CB1 receptor antagonist SR141716A attenuates the memory impairment produced by delta9-tetrahydrocannabinol or anandamide Psychopharmacology (Berl) 140